Screener
Immunome IMNM Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The source filing: Immunome’s 10-K, filed March 3, 2026.
- Filed
- Mar 3, 2026, 4:07 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-088172
| Line item | December 31, 2025 | December 31, 2024 |
|---|---|---|
| Current liabilities: | ||
| Accounts payable | $3,339 | $14,189 |
| Accrued expenses and other current liabilities | 41,651 | 33,177 |
| Deferred revenue, current | — | 6,941 |
| Total current liabilities | 44,990 | 54,307 |
| Operating lease liabilities, net of current portion | 3,855 | 4,769 |
| Total liabilities | 48,845 | 59,076 |
| Stockholders’ equity: |
Item 16. Form 10-K Summary
FAQ
- What is Immunome's deferred revenue?
- Immunome (IMNM) reported deferred revenue of $0 in Q4 2025.
- How has Immunome's deferred revenue changed year-over-year?
- Immunome's deferred revenue decreased by 100.0% year-over-year, from $6.94M to $0.
- What is the long-term trend for Immunome's deferred revenue?
- Over 2 years (2023 to 2025), Immunome's deferred revenue has grown at a -100.0% compound annual growth rate (CAGR), from $10.49M to $0.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Immunome's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude